We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Study to Evaluate the Safety and Efficacy of the CiTop™ ExPander™ Guidewire for Crossing Chronic Total Occlusions in Coronary Arteries

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00733070
Recruitment Status : Terminated (no interest to develop the product)
First Posted : August 12, 2008
Last Update Posted : July 9, 2013
Information provided by:

Brief Summary:
A multicenter multinational study to evaluate the safety and efficacy of the CiTop™ ExPander™ Guidewire for crossing chronic total occlusion in Coronary arteries.

Condition or disease Intervention/treatment
Coronary Chronic Total Occlusion Device: CiTop™ ExPander™ Guidewire

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter Multinational Study to Evaluate the Safety and Efficacy of the CiTop™ ExPander™ Guidewire for Crossing Chronic Total Occlusions in Coronary Arteries
Study Start Date : August 2008
Primary Completion Date : June 2013
Study Completion Date : June 2013

Intervention Details:
    Device: CiTop™ ExPander™ Guidewire
    Chronic Total Occlusion guidewire

Primary Outcome Measures :
  1. Angiographic documentation of placement of CiTop™ distal to occlusion with no device related major complications [ Time Frame: during procedure, 1day, 1week and 30 days post procedure ]

Secondary Outcome Measures :
  1. Successful stenting [ Time Frame: During procedure, Day1, Day7 and Day30 post procedure ]
  2. Wire crossing duration [ Time Frame: during procedure ]
  3. Fluoroscopy time [ Time Frame: during procedure ]
  4. Amount of contrast [ Time Frame: during procedure ]
  5. Maneuverability of the CiTop™ up to the occlusion [ Time Frame: during procedure ]
  6. No mechanical damage to the device during [ Time Frame: during procedure ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   21 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Informed consent obtained prior to any trial activities.
  2. Patients, male or female between 21 and 80 years of age, with no significant co-morbidities (see exclusion criteria).
  3. Patient has an angiographic documented Chronic Total Occlusion showing distal TIMI flow 0 to 1.

Exclusion Criteria:

  1. Patient unable to give informed consent.
  2. Current participation in another study with any investigational drug or device.
  3. Factors making follow-up and/or repeat angiography difficult or unlikely.
  4. Contra-indication to emergency artery by pass surgery.
  5. Lack of surgical backup.
  6. Contra-indication to treatment with Aspirin, or Clopidogrel and/or Heparin.
  7. Lesion > 40mm in length (both calcified lesion and adjacent thrombus).
  8. Treated vessel referenced diameter less than 2.5 mm.
  9. Visualization of the distal lumen less than the Rentrop Classification Grade 2 collateralization.
  10. Non-visible entry point of target lesion.
  11. Totally occluded bypass graft as target vessel.
  12. Acute MI less than 1 week before procedure.
  13. Patient has significant LV dysfunction, 35% LVEF or less.
  14. Patient with cancer or other sever chronic disease with life expectance of 2 years.
  15. Patient has chronic renal failure with serum creatinine ≥2.
  16. Hemoglobin ≤11.
  17. Patient is known or suspected not to tolerate the contrast agent.
  18. Morbid Obesity (BMI > 40).
  19. Drug abuse or alcoholism.
  20. Patients under custodial care.
  21. Pregnant women or women with childbearing potential with a positive pregnancy test at the time of procedure.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00733070

HELIOS Klinikum Wuppertal
Wuppertal, Germany, D-42117
South Africa
Sunward Park Hospital
Boksburg, South Africa
Sunninghill Hospital
Sunninghill, South Africa, 2157
Sponsors and Collaborators

Responsible Party: Nathalie Gilat, Ovalum
ClinicalTrials.gov Identifier: NCT00733070     History of Changes
Other Study ID Numbers: OVC-003-00
First Posted: August 12, 2008    Key Record Dates
Last Update Posted: July 9, 2013
Last Verified: July 2013

Keywords provided by Ovalum:
Chronic Total Occlusion